Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Brain Metastasis|Breast Cancer|Non Small Cell Lung Cancer
Interventions: DRUG: Cabazitaxel|PROCEDURE: Contrast-enhanced whole brain MRI
Sponsor: Jules Bordet Institute
Collaborators: Sanofi